IGC Pharma, Inc. (IGC)

↓ Download CSV

CIK 0001326205 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated MD
  • Fiscal year ends Dec 31

In fiscal 2025, IGC Pharma, Inc. reported revenue of $1.27M, down 5.5% from the prior year. The company ran a net loss, with a net margin of -560.3% and a gross margin of 48.7%. It held $9.71M in total assets against $2.29M in total liabilities.

Key ratios (FY2025)

48.7%
Gross margin
-585.8%
Operating margin
-560.3%
Net margin
-95.9%
Return on equity
-5.5%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$1.27M$1.34M$911.0K$397.0K$898.0K$4.07M$5.12M$2.19M$580.4K$6.37M
Cost of Revenue$652.0K$612.0K$469.0K$203.0K$785.0K$3.96M$4.98M$2.11M$362.1K$5.52M
Gross Profit$619.0K$733.0K$442.0K$194.0K$113.0K$115.0K$132.0K$82.0K$218.2K
Operating Income-$7.45M-$9.80M-$11.57M-$15.43M-$8.72M-$6.86M-$4.64M-$1.79M-$2.05M-$2.91M
Net Income-$7.12M-$13.00M-$11.51M-$15.02M-$8.81M-$7.32M-$4.10M-$1.79M-$1.87M-$2.81M
EPS (Diluted)$-0.09$-0.22$-0.07$-0.17
Total Assets$9.71M$9.90M$17.18M$26.83M$35.87M$28.98M$34.47M$10.85M$11.28M$18.86M
Total Liabilities$2.29M$2.58M$2.27M$2.94M$3.06M$2.45M$893.0K$2.79M$3.93M$4.91M
Shareholders' Equity$7.42M$7.32M$14.91M$23.89M$32.80M$26.54M$8.06M$7.36M$13.48M
Cash & Equivalents$900.0K$1.20M$3.20M$10.46M$14.55M$7.26M$25.61M$1.66M$538.0K$1.49M
Operating Cash Flow-$4.79M-$5.20M-$7.05M-$7.46M-$10.80M-$8.68M-$3.33M-$1.93M-$1.39M-$157.7K
Capital Expenditures$112.0K$138.0K$310.0K$236.0K$1.47M$4.39M$15.0K$136.0K$145.7K$122.2K
Shares Outstanding95.04M66.69M53.08M51.05M47.83M39.32M39.50M30.76M28.27M23.27M